Menu Search
Equities

Guerbet SA

GBT:PAR

Guerbet SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)26.00
  • Today's Change-0.300 / -1.14%
  • Shares traded12.53k
  • 1 Year change+44.44%
  • Beta0.7504
Data delayed at least 15 minutes, as of Nov 22 2024 15:34 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Guerbet SA grew revenues 4.30% from 753.28m to 785.69m while net income improved from a loss of 41.12m to a gain of 23.87m.
Gross margin78.58%
Net profit margin3.73%
Operating margin7.10%
Return on assets3.03%
Return on equity8.64%
Return on investment4.96%
More ▼

Cash flow in EURView more

In 2023, Guerbet SA increased its cash reserves by 23.17%, or 9.60m. Cash Flow from Financing totalled 44.75m or 5.70% of revenues. In addition the company generated 27.44m in cash from operations while cash used for investing totalled 59.93m.
Cash flow per share7.18
Price/Cash flow per share3.72
Book value per share30.82
Tangible book value per share23.27
More ▼

Balance sheet in EURView more

Guerbet SA has a Debt to Total Capital ratio of 50.73%, a higher figure than the previous year's 8.39%.
Current ratio2.52
Quick ratio1.16
Total debt/total equity1.03
Total debt/total capital0.5073
More ▼

Growth rates in EUR

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 153.92%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)2.20%
Div growth rate (5 year)-10.07%
Payout ratio (TTM)19.29%
EPS growth(5 years)-13.85
EPS (TTM) vs
TTM 1 year ago		173.65
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.